Sun Pharma announces voluntary withdrawal of 28 ANDAs

NEW DELHI: Drug major, Sun Pharmaceutical Industries today said one of the company’s wholly-owned subsidiaries has voluntarily requested the USFDA to withdraw approval for 28 Abbreviated New Drug Applications (ANDAs).

The company, in a regulatory filing to stock exchanges, said the withdrawn drugs were the older products from the erstwhile Ranbaxy laboratories, and are not being marketed in US since 2008.

It, however, didn't reveal any details about the drugs and the subsidiary.

With immense pride “India Live” celebrated its 10th national conference in Mumbai from 28th February to 3rd March 2019. The conference turned out to be a gold mine of information, with emphasis on academics, education and exchange of knowledge with leaders in interventional cardiology from both India and abroad.